Final MRI Results at 6 Months from A Phase 2 Multicenter Study of Ublituximab, A Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mab), in Patients with Relapsing Forms of Multiple Sclerosis (RMS), Demonstrates Complete Elimination of Gd-Enhancing Lesions (P3.409)